anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Post-traumatic stress disorder (PTSD) is an anxiety disorder that can develop after exposure to a terrifying event in which grave physical harm occurred or was threatened. People with PTSD have persistent frightening thoughts and memories of their past ordeal and often feel emotionally numb, especially with people to whom they were once close. PTSD was first recognized in male combat veterans. Today, however, the majority of people who have PTSD are young women who have experienced non combat-related trauma, such as sexual or physical assault or a life-threatening illness or accident. The disorder can be short-lived, but PTSD can also become chronic, with long lasting symptoms that are often treatment-resistant, possibly causing severe functional disability. Frequent trauma-related nightmares and other debilitating sleep disruptions are examples of chronic PTSD symptoms for which an effective treatment has not been developed. Sertraline and paroxetine, both selective serotonin reuptake inhibitors (SSRIs), are the only drugs approved by the FDA for treating PTSD. Neither of them, however, has been effective in reducing PTSD-related sleep disruption. Studies have shown that the drug prazosin has been effective in reducing distressing trauma-related nightmares in older male combat veterans. This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals already being treated with SSRIs.

Participants in this double-blind study will first undergo 12 weeks of treatment with psychotherapy and a standard SSRI. After 12 weeks, participants will be randomly assigned to receive either prazosin or placebo in addition to psychotherapy and standard SSRI treatment for a total of 8 weeks. Study visits will occur weekly for the first 12 weeks, and then at Weeks 1, 2, 4, 6, and 8 during the 8-week phase. Additionally, follow-up visits will be held 4 and 18 weeks post-intervention. PTSD symptoms, disorder severity, and frequency of sleep disturbances will be assessed.
Pre-emptive genotyping provides relevant genomic data to physicians to facilitate prescribing and to facilitate checking of prescriptions by pharmacists to ensure drug safety and efficacy. This essential information should be incorporated into electronic healthcare systems and should be readily available. The effectiveness of pre-emptive genotyping to reduce adverse drug reactions (ADRs) is unknown in Singapore. Hence, this study is designed to evaluate whether it is feasible to implement large scale pre-emptive genotyping program at a hospital in Singapore and aim to integrate genomic medicine into clinical practice to improve drug safety and efficacy.

This study involves the testing of feasibility of pharmacogenomic genotyping in hospitals whereby our pharmacogenomics panel tests for 5 genes (CYP2D6, CYP2C9, CYP2C19, SLCO1B1 and HLA-B\*58:01) which influences patient's response to more than 165 medications. Reports will be generated for all drugs that have been reported to be in CPIC Level A/B of association with the genes/haplotypes. The patients who are given these tests for free are recommended due to having experienced at least one of the diseases in our list or is at a risk of developing them.
1,172,635. N-Alkyl isopicramic acids. GILLETTE INDUSTRIES Ltd. 10 July, 1968, No. 32963/68. Heading C4P. N-Monoalkyl isopicramic acids in which the alkyl group contains up to 6 carbon atoms are prepared by nitrating an N-monoalkyl-paminophenol with nitric acid in the presence of sulphuric acid at a temperature of from - 20‹ C. to + 30‹ C. so as to introduce two nitro groups into the starting material. NMonoalkyl isopicramic acids in which the alkyl group is an isopropyl group or is a linear, branched or cyclic alkyl group of 4-6 carbon atoms are claimed per se.
A crucial parameter in determining the prognosis of oral cavity cancer is depth of invasion (DOI). This research aimed to correlate pathological DOI at different intra-oral anatomical sites for oral squamous cell carcinoma (OSCC) with the risk of regional lymph node metastasis (LNM). This study also investigated the correlation of 3-year overall survival (OS) and disease-specific survival (DSS) with tumor depth. DOI measurement of the primary tumor at different intra-oral anatomic sites of clinically node negative patients who underwent curative surgery with elective neck dissection (END) was carried out as per AJCC 8th Edition staging guidelines in 3 DOI groups of ≤5 mm(A), >5 to ≤10 mm(B) and >10 mm(C). Association of groupwise DOI values with histopathological parameters including LNM and 3 years survival was evaluated. Univariate and multivariate logistic regression analysis (Odds ratio (OR) = 1.1 95 % CI: 1.0-1.2, p < 0.05) showed DOI to be a significant predictor for sub-clinical nodal metastasis observed in 136/382 OSCC patients. Receiver operating curve suggested that at 5 mm DOI (4 mm for early-stage OSCC), the risk of occult LNM was >20 % for all intra-oral sites combined. DOI <5 mm group demonstrated a superior 3-year OS (OR = 19.8 % CI: 7.8-49.9) and DSS (OR = 14.7 % CI: 5.9-37.0). Thus, DOI is an independent predictor of nodal metastasis and has significant association with LNM, OS and DSS. Our findings suggest that a DOI of ≥4 mm is an accurate cut-off value for performing END in early-stage OSCC and > 5 mm for advanced cases across all evaluated oral anatomic sites.
The use of benzodiazepines, including triazolam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence (9.2)].

Before prescribing triazolam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of triazolam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of triazolam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.
PURPOSE: Hepato-protective fermented food containing a rice bran fermentation product, and a producing method thereof are provided to inject fermented soybean powder to a rice bran medium to obtain the rice bran fermentation product. CONSTITUTION: A producing method of hepato-protective fermented food containing a rice bran fermentation product comprises a step of injecting fermented soybean powder to a rice bran medium, and fermenting the mixture at 20-30 deg. C for 40 days. The producing method a step of pre-fermenting the mixture at 75-90 deg. C, and a step of post-fermenting the mixture at 75-90 deg. C.
PROBLEM TO BE SOLVED: To obtain a therapeutic agent capable of killing schistosome, by including resin (myrrh) obtained from the trunk tree of the family Burseraceae. SOLUTION: The myrrh obtained from the trunk tree of Commiphora molmol (family Burseraceae) growing naturally in North-Eastern Africa and Arabia is effective for treatment of schistosomiasis haematobia. The myrrh contains volatile oil, resin, gum, and impurities. The volatile oil is extracted by steam distillation or petroleum ether extraction. The resin can be obtained by alcohol extraction or petroleum ether extraction. Pharmaceutical manufacturing of this therapeutic agent can be conducted by formulating an inert base in the extracts into a form of soft gelatin capsule. The volatile oil and resin, both of which are obtained together from the myrrh in a specific ratio, have a very strong effect as a schistosome-killing agent.
Contrary to the initial belief that myofibroblasts are terminally differentiated cells, myofibroblasts have now been widely recognized as an activation state that is reversible. Therefore, strategies targeting myofibroblast to be a quiescent state may be an effective way for antihypertrophic scar therapy. Graphene quantum dots (GQDs), a novel zero-dimensional and carbon-based nanomaterial, have recently garnered significant interest in nanobiomedicine, owing to their excellent biocompatibility, tunable photoluminescence, and superior physiological stability. Although multiple nanoparticles have been used to alleviate hypertrophic scars, a GQD-based therapy has not been reported. Our in vivo studies showed that GQDs exhibited significant antiscar efficacy, with scar appearance improvement, collagen reduction and rearrangement, and inhibition of myofibroblast overproliferation. Further in vitro experiments revealed that GQDs inhibited α-SMA expression, collagen synthesis, and cell proliferation and migration, inducing myofibroblasts to become quiescent fibroblasts. Mechanistic studies have demonstrated that the effect of GQDs on myofibroblast proliferation blocked cell cycle progression by disrupting the cyclin-CDK-E2F axis. This study suggests that GQDs, which promote myofibroblast-to-fibroblast transition, could be a novel antiscar nanomedicine for the treatment of hypertrophic scars and other types of pathological fibrosis.
Systems and methods relate to a mobile intraoral scanning site. The mobile intraoral scanning site includes a vehicle and one or more three-dimensional intraoral scanners provided on the vehicle and configured to perform intraoral dentition scans of users on the vehicle. The vehicle can include at least two compartments configured to be used as scan stations for performing the intraoral dentitions scans of the users on the vehicle. The vehicle can be retrofitted to be used for the mobile intraoral scanning site. The one or more three-dimensional intraoral scanners can be wall-mounted on the vehicle. The vehicle can be provided with an internet connection such that the intraoral dentition scans are uploaded to a cloud server via the internet connection. Messages can be sent to a plurality of individuals inviting the plurality of individuals to schedule an appointment to receive an intraoral dentition scan at the vehicle.
It was recently reported that "early", i.e. in the first 48h of life, coagulation screening may identify infants at risk of severe IVH. Unfortunately, in the past screening for coagulation abnormalities and correction of haemostatic defects by prothrombin complex concentrate, cryoprecipitate or platelet concentrates) and fresh frozen plasma (FFP) had limited effects in preterm infants. This could have been due to the short duration of action, incomplete restoration of coagulation or the water and osmotic load associated with FFP administration. However recently, using a coagulopathy screening strategy (one blood sample within the first 2h after birth) and substitution with FFP decreased the risk of developing IVH in infants born at 23 to 26 weeks of gestation. Recombinant Factor VII (rFVII) provides a new therapeutic option to overcome FFP associated side effects. Small trials, including infants with pulmonary hemorrhage, showed the safety and effectiveness of rFVII in VLBW infants; however no randomised controlled trials have been published so far. As outlined above, bleeding complications are still a major problem in extremely low birth weight (ELBW) infants and coagulation abnormalities are associated with bleeding. Up to now, only data about early and single screening exist and coagulation monitoring with multiple blood sampling was not applied.

In neonatal practice, coagulation abnormality in preterm babies is primarily investigated by measuring prothrombin time (PT). In fact, FVII activity, which is an important determinant of PT, is strongly associated with bleeding risk. Thus, a method to measure PT with small volume samples (10μL) provides the possibility for serial monitoring even in ELBW infants.

Substitution of FFP seemed beneficial in ELBW infants and first trials with rFVII revealed promising results in this patient population. Thus, coagulation monitoring might lead to early and adequate therapy and therefore to better outcome.
PROBLEM TO BE SOLVED: To obtain a new vector which has a base sequence coding for a specific amino acid sequence and a polynucleotide coding for a hematopoiesis accelerator (e.g. polypeptide having human multipotent granular colony stimulator activity, and can be used for production of protein useful for, e.g. leukocyte increasing agent and therepeutic agent of hematopoiesis injury. SOLUTION: This vector is a novel manifestation vector having a base sequence coding for an amino acid sequency shown by formula [(n) is 0 or 1] or the above amino acid sequence where one or more amino acid residue in the 1st to 174th amino acid sequences are lost, substituted, added and/or inserted, and a polynucleotide coding for a hematopoiesis accelerator (e.g. polypeptide having human multipotent granular colony stimulator (hpG-CSF) activity. It can be used for production of protein useful for, e.g. leukocyte increasing agent and therapeutic agent of hematopoiesis injury. It is obtained by cutting a plasmid containing an hpG-CSF gene with a restriction enzyme, and integrating it in a manifestation vector used for manifestation of Escherichia coil, capable of manifesting in a host, e.g. Escherichia coli.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to oncology and can be used in treatment of soft tissue sarcomas as one of complex treatment components. For this purpose sampling of 400 ml of blood into vial with hemopreservative is carried out with its further centrifugation at 1500 rotations per minute during 30 minutes. After that, plasma is divided into two equal parts into sterile vials: into one of them introduced are 600 mg/m2 of cyclophpsphane, into the other - methotrexate 40 mg/m2, and blood cells are connected with doxorubicin - 40 mg/m2. All mixtures are incubated for 30 minutes at 37C. After that on the first and seventh day of treatment intravenously simultaneously introduced are blood cells with doxorubicin and mixtures of autoplasm with cyclophosphane and then with methotrexane are injected around tumour on its circumference. ^ EFFECT: method makes it possible to increase efficiency of said pathology treatment due to ensuring considerable reduction of tumour size before surgery. ^ 1 ex
This study will use behavioral economic strategies to promote utilization of traffic-light nutrition ranking in the Greater Boston Food Bank (GBFB) order system to improve the dietary quality of food ordered by GBFB agencies. Supporting Wellness at Pantries (SWAP) is a program to guide both traffic light labeling for use on ordering platforms and pantry shelves, as well as food pantry layout to inform clients and encourage healthy food choice.This study is a collaboration with the Greater Boston Food Bank (GBFB) to test BE strategies (choice architecture, framing, social norms) for implementation of an evidence-based intervention (traffic light nutrition ranking, SWAP). We will determine if behavioral economic interventions on the GBFB online ordering platform increase agencies' use of traffic light nutrition labels when placing orders and increases their healthy food orders. We will conduct a 12-month randomized controlled trial comparing agencies' ordering experiences and outcomes with the current user interface (control) to a "SWAP-enhanced" user interface (intervention). All GBFB partner agencies will be randomized to see either the control or intervention interfaces when they log on to ShopGBFB, GBFB's online food ordering platform. At the end of 12 months, agency staff will complete a survey about their online ordering experiences at GBFB. In the next phase, the SWAP-enhanced ShopGBFB interface will be updated, adapted, and implemented for all 600 agencies. Agency ordering outcomes will be monitored for 30 additional months.
BACKGROUND: The inclusion of biomarkers could improve diagnostic accuracy of attention-deficit/hyperactivity disorder (ADHD). One potential biomarker is the ADHD polygenic score (PGS), a measure of genetic liability for ADHD. This study aimed to investigate if the ADHD PGS can provide additional information alongside ADHD rating scales and examination of family history of ADHD to distinguish between ADHD cases and controls.
METHODS: Polygenic scores were calculated for 576 adults with ADHD and 530 ethnically matched controls. ADHD PGS was used alongside scores from the Wender-Utah Rating Scale (WURS) and the Adult ADHD Self-Report Scale (ASRS) as predictors of ADHD diagnosis in a set of nested logistic regression models. These models were compared by likelihood ratio (LR) tests, Akaike information criterion corrected for small samples (AICc), and Lee R². These analyses were repeated with family history of ADHD as a covariate in all models.
RESULTS: The ADHD PGS increased the variance explained of the ASRS by 0.58% points (pp) (R2ASRS = 61.11%, R2ASRS + PGS=61.69%), the WURS by 0.61pp (R2WURS = 77.33%, R2WURS + PGS= 77.94%), of ASRS and WURS together by 0.57pp (R2ASRS + WURS=80.84%, R2ASRS + WURS+PGS=81.40%), and of self-reported family history by 1.40pp (R2family = 28.06%, R2family + PGS=29.46%). These increases were statistically significant, as measured by LR tests and AICc.
CONCLUSION: We found that the ADHD PGS contributed additional information to common diagnostic aids. However, the increase in variance explained was small, suggesting that the ADHD PGS is currently not a clinically useful diagnostic aid. Future studies should examine the utility of ADHD PGS in ADHD prediction alongside non-genetic risk factors, and the diagnostic utility of the ADHD PGS should be evaluated as more genetic data is accumulated and computational tools are further refined.
BACKGROUND: Patients with breast pain are usually seen in 'one-stop clinic' (OSC) with breast imaging. In the absence of associated red flag features, the incidence of breast cancer is extremely low. With increase in referrals the OSC capacity is over-stretched. We developed a consultant nurse-led dedicated 'breast pain clinic' in September 2021 without routine breast imaging. After meticulous history and examination, patients obtained detailed counselling and advice regarding breast pain management. If any abnormality was noted then appointment was given for OSC.
AIM: To assess the effectiveness of a consultant nurse-led dedicated 'breast pain clinic'.
METHODS: A prospective study of all consecutive patients seen in 'breast pain clinic' from September 2021 until September 2022. Feedback was sought from all patients.
RESULTS: Altogether 429 patients were seen. The mean age was 48.7 years (range 18-86). 87.6% (n = 376) patients required no breast imaging. Only 12.4% (n = 53) patients needed referral to OSC and subsequently 2 patients (0.46%) were diagnosed with breast cancer. Ninety-eight percent of patients felt reassured and 99.2% patients were extremely likely/likely to recommend this service to family and friends. Out of 376 patients who were discharged from breast pain clinic, 12 patients were referred again over a median follow-up period of 15 months, and 2 out of them were diagnosed with breast cancer.
CONCLUSION: A consultant nurse-led 'breast pain clinic' provides service improvement as it eases the pressure on the OSC. Most patients were managed without breast imaging with high level of patient satisfaction and low rereferral rate.
Objective: To explore the clinical and genetic characteristics of asparagine synthase deficiency. Methods: Case series studies. Retrospective analysis and summary of the clinical data of 6 cases with asparagine synthase deficiency who were diagnosed by genetic testing and admitted to the Third Affiliated Hospital of Zhengzhou University from May 2017 to April 2023 were analyzed retrospectively. The main clinical features, laboratory and imaging examination characteristics of the 6 cases were summarized, and the gene variation sites of them were analyzed. Results: All of the 6 cases were male, with onset ages ranging from 1 month to 1 year and 4 months. All of the 6 cases had cognitive and motor developmental delay, with 3 cases starting with developmental delay, 3 cases starting with convulsions and later experiencing developmental arrest or even regression. All of 6 cases had epilepsy, in whom 2 cases with severe microcephaly developed epileptic encephalopathy in the early stages of infancy with spasms as the main form of convulsions, 4 cases with mild or no microcephaly gradually evolved into convulsions with no fever after multiple febrile convulsions with focal seizures, tonic clonic seizures and tonic seizure as the main forms of convulsions. Three cases of 4 gradually developed into stagnation or even regression of development and ataxia after multiple convulsions with no fever. There were normal cranial imaging in 2 cases, dysplasia of the brains in 1 cases, frontal lobe apex accompanied by abnormal white matter signal in the frontal lobe and thin corpus callosum in 1 case, thin corpus callosum and abnormal lateral ventricular morphology in 1 case, and normal in early stage, but gradually developing into cerebellar atrophy at the age of 5 years and 9 months in 1 case. Two cases underwent visual evoked potential tests, the results of which were both abnormal. Three cases underwent auditory evoked potential examination, with 1 being normal and 2 being abnormal. All of 6 cases had variations in the asparagine synthase gene, with 2 deletion variations and 7 missense variations. The variations of 2 cases had not been reported so far, including c.1341_1343del and c.1283A>G, c.1165_1167del and c.1075G>A. The follow-up time ranged from 3 months to 53 months. Two cases who had severe microcephaly died in infancy, while the other 4 cases with mild or no microcephaly were in survival states until the follow-up days but the control of epilepsy was poor. Conclusions: Asparagine synthase deficiency has a certain degree of heterogeneity in clinical phenotype. Children with obvious microcephaly often present as severe cases, while children with mild or no microcephaly have relatively mild clinical manifestations. The variation of asparagine synthetase gene is mainly missense variation.
The invention provides a small interfering RNA, an shRNA (Short Hairpin Ribonucleic Acid), an shRNA encoded DNA (Deoxyribonucleic acid), a recombinant vector, a recombinant slow virus and a host cell for knocking down Syntaxin8, as well as application of the small interfering RNA, the shRNA (Short Hairpin Ribonucleic Acid), the shRNA encoded DNA (Deoxyribonucleic acid), the recombinant vector, the recombinant slow virus and the host cell. The small interfering RNA has a nucleotide sequence with the length of 19-27 bp. The nucleotide sequence is complementary with a messenger RNA for translating the Syntaxin8. The recombinant slow virus carrier can be transcribed to obtain Syntaxin8-shRNA. The Syntaxin8-shRNA can be processed by the host cell to generate the small interfering RNA capable of silencing Syntaxin8 expression. The small interfering RNA can target the mRNA of the Syntaxin8, induce mRNA degradation, generate the gene silence effect, and reduce the expression level of Syntaxin8.
Participants in this group will receive the standard of care treatment for pain management for TKA including a preoperative adductor canal block. Participants will be in this group for up to 24 hours after surgery.